Vical Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial

By: via Benzinga
Vical Incorporated (Nasdaq: VICL) today announced the completion of enrollment in a Phase 1/2 trial of its Vaxfectin^®-formulated ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.